Long-term treatment with bevacizumab for patients with metastatic colorectal cancer: Case report

被引：11

作者：

Hurwitz, Herbert I.

Honeycutt, Wanda

Haley, Sherri

Favaro, Justin

机构：

[1] Duke Univ, Med Ctr, Durham, NC 27706 USA

[2] Duke Comprehens Canc Ctr, Durham, NC USA

来源：

CLINICAL COLORECTAL CANCER | 2006年 / 6卷 / 01期

关键词：

antiangiogenic agents; 5-fluorouracil; irinotecan; leucovorin;

D O I：

10.3816/CCC.2006.n.023

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Bevacizumab is a monoclonal antibody to vascular endothelial growth factor that has demonstrated increased overall survival when added to standard chemotherapy regimens for metastatic colorectal cancer. Herein we report the cases of 2 patients who demonstrated prolonged survival times of almost 5 and 6 years, respectively, on various chemotherapy regimens that also included bevacizumab. Throughout most of their disease course, these patients maintained a good quality of life, with some adjustments of chemotherapy doses because of side effects. Bevacizumab was generally well tolerated in long-term use.

引用

收藏

页码：66 / 69

页数：4

相关论文

共 18 条

[1] Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial [J].

Douillard, JY ;

Cunningham, D ;

Roth, AD ;

Navarro, M ;

James, RD ;

Karasek, P ;

Jandik, P ;

Iveson, T ;

Carmichael, J ;

Alakl, M ;

Gruia, G ;

Awad, L ;

Rougier, P .

LANCET, 2000, 355 (9209) :1041-1047

[2]

*GEN INC, OP MULT EXT STUD RHU

[3]

Giantonio BJ, 2005, J CLIN ONCOL, V23, p1S

[4] A Randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer [J].

Goldberg, RM ;

Sargent, DJ ;

Morton, RF ;

Fuchs, CS ;

Ramanathan, RK ;

Williamson, SK ;

Findlay, BP ;

Pitot, HC ;

Alberts, SR .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) :23-30

[5] Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment [J].

Grothey, A ;

Sargent, D ;

Goldberg, RM ;

Schmoll, HJ .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (07) :1209-1214

[6]

HEDRICK EE, 2004, P AN M AM SOC CLIN, V23, P249

[7] Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J].

Hurwitz, H ;

Fehrenbacher, L ;

Novotny, W ;

Cartwright, T ;

Hainsworth, J ;

Heim, W ;

Berlin, J ;

Baron, A ;

Griffing, S ;

Holmgren, E ;

Ferrara, N ;

Fyfe, G ;

Rogers, B ;

Ross, R ;

Kabbinavar, F .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2335-2342

[8] Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy [J].

Jain, RK .

SCIENCE, 2005, 307 (5706) :58-62

[9] Addition of bevacizurnab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial [J].

Kabbinavar, FF ;

Schulz, J ;

McCleod, M ;

Patel, T ;

Hamm, JT ;

Hecht, JR ;

Mass, R ;

Perrou, B ;

Nelson, B ;

Novotny, WF .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) :3697-3705

[10] Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer [J].

Kabbinavar, FF ;

Hambleton, J ;

Mass, RD ;

Hurwitz, HL ;

Bergsland, E ;

Sarkar, S .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) :3706-3712